2-(溴甲基)-4-氯吡啶 | 856850-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(溴甲基)-4-氯吡啶
• 英文名称: 2-(bromomethyl)-4-chloropyridine
• CAS: 856850-18-5
• 化学式: C₆H₅BrClN
• 分子量: 206.469
• InChiKey: GLSNQEHWJXTBDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(溴甲基)-4-氯吡啶 在 水 作用下， 生成 4-氯-2-吡啶甲醇
  参考文献：
  名称：

  Hasegawa, Pharmaceutical Bulletin, 1953, vol. 1, p. 293,296

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-2-吡啶甲醇 在 三溴化磷 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以83%的产率得到2-(溴甲基)-4-氯吡啶
  参考文献：
  名称：

  Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors

  摘要：

  To validate the hypothesis that Tyr748 is a crucial residue to aid the discovery of highly selective phosphodiesterase 8A (PDE8A) inhibitors, we identified a series of 2-chloroadenine derivatives based on the hit clofarabine. Structure-based design targeting Tyr748 in PDE8 resulted in the lead compound 3a (IC50 = 0.010 μM) with high selectivity with a reasonable druglike profile. In the X-ray crystal structure, 3a bound to PDE8A with a different mode from 3-isobutyl-1-methylxanthine (a pan-PDE inhibitor) and gave a H-bond of 2.7 Å with Tyr748, which possibly interprets the 220-fold selectivity of 3a against PDE2A. Additionally, oral administration of compound 3a achieved remarkable therapeutic effects against vascular dementia (VaD), indicating that PDE8 inhibitors could serve as potential anti-VaD agents.

  DOI：

  10.1021/acs.jmedchem.0c01573

文献信息

• Pyrimidine-thioalkyl and alkylether compounds
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1247804A1

  公开（公告）日：2002-10-09

  The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula I and pyrimidine-thioalkyl and alkylethers of Formula IA, namely the compounds of Formula I where R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is selected from the group consisting of -H, or halo (preferably -Cl); with the overall provisio that R4 and R6 are not both -H; The compounds of Formula IA are useful in the treatment of individuals who are HIV positive.

  该发明涉及Formula I的嘧啶硫代烷基和烷基醚化合物，以及Formula IA的嘧啶硫代烷基和烷基醚化合物，即Formula I中R4选自-H或-NR15R16的基团，其中R15为-H，R16为-H，C1-C6烷基，-NH2或R15和R16一起与-N形成1-吡咯啉基、1-吗啉基或1-哌啶基；以及R6选自-H或卤素（优选-Cl）的基团，总体规定是R4和R6不能同时为-H；Formula IA的化合物在治疗HIV阳性个体中是有用的。
• 一种2-氯腺嘌呤衍生物、制备方法及应用
  申请人：中山大学

  公开号：CN112266386B

  公开（公告）日：2022-03-25

  本发明属于药物化学技术领域，具体涉及一种2‑氯腺嘌呤衍生物、制备方法及应用。本发明提供的2‑氯腺嘌呤衍生物对磷酸二酯酶8型具有良好的抑制作用，并且还有较好的肝微粒体稳定性和成药性质，可应用于制备治疗和/或预防与磷酸二酯酶8型相关疾病的药物中，具有较好的开发潜力，增加治疗磷酸二酯酶8型相关疾病药物的可选择范围。
• One-Pot Directed Alkylation/Deprotection Strategy for the Synthesis of Substituted Pyrrole[3,4-<i>d</i>]pyridazinones
  作者：Reji N. Nair、Thomas D. Bannister

  DOI：10.1002/ejoc.201403491

  日期：2015.3

  In the course of an SAR study of pyrrole[3,4-d]pyridazinones we optimized conditions for a one pot directed lithiation / alkylation reaction that also promoted in situ cleavage of a Boc-protecting group on the pyrrole ring. The efficiency of the process allowed access to a number of substituted analogues of interest as possible antitumor agents.

  在吡咯 [3,4-d] 哒嗪酮的 SAR 研究过程中，我们优化了单锅定向锂化/烷基化反应的条件，该反应还促进了吡咯环上 Boc 保护基团的原位裂解。该过程的效率允许获得许多感兴趣的取代类似物作为可能的抗肿瘤剂。
• New compounds
  申请人：AstraZeneca AB and NPS Pharmaceuticals, Inc.

  公开号：US20040106607A1

  公开（公告）日：2004-06-03

  The present invention relates to new compounds of formula I, 1 wherein P, Q, X 1 , X 2 , X 3 , X 4 , X 5 , R, R 1 , R 2 , R 3 , R 4 , R 5 , G, M 1 , M 2 , M 3 , m and n, are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式I的新化合物，其中P、Q、X1、X2、X3、X4、X5、R、R1、R2、R3、R4、R5、G、M1、M2、M3、m和n在公式I中定义，以及其制备过程和其中制备的新中间体，含有所述化合物的药物配方以及在治疗中使用所述化合物的用途。
• 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE
  申请人：AYUMI Pharmaceutical Corporation

  公开号：EP3640253A1

  公开（公告）日：2020-04-22

  The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

  本发明的 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂卓衍生物或其盐类具有 BRD4 抑制活性，因此可用作药物，特别是用作与 BRD4 相关疾病的预防和/或治疗药物。